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Abstract
Angiotensin-(1–7) [Ang-(1–7)] is a biologically active heptapeptide that may counterbalance the physiological actions of
angiotensin II (Ang II) within the renin-angiotensin system (RAS). Here, we evaluated whether activation of the Mas receptor
with the oral agonist, AVE 0991, would have renoprotective effects in a model of adriamycin (ADR)-induced nephropathy.
We also evaluated whether the Mas receptor contributed for the protective effects of treatment with AT1 receptor blockers.
ADR (10 mg/kg) induced significant renal injury and dysfunction that was maximal at day 14 after injection. Treatment with
the Mas receptor agonist AVE 0991 improved renal function parameters, reduced urinary protein loss and attenuated
histological changes. Renoprotection was associated with reduction in urinary levels of TGF-b. Similar renoprotection was
observed after treatment with the AT1 receptor antagonist, Losartan. AT1 and Mas receptor mRNA levels dropped after ADR
administration and treatment with losartan reestablished the expression of Mas receptor and increased the expression of
ACE2. ADR-induced nephropathy was similar in wild type (Mas+/+) and Mas knockout (Mas2/2) mice, suggesting there was
no endogenous role for Mas receptor activation. However, treatment with Losartan was able to reduce renal injury only in
Mas+/+, but not in Mas2/2 mice. Therefore, these findings suggest that exogenous activation of the Mas receptor protects
from ADR-induced nephropathy and contributes to the beneficial effects of AT1 receptor blockade. Medications which
target specifically the ACE2/Ang-(1–7)/Mas axis may offer new therapeutic opportunities to treat human nephropathies.
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Introduction
Angiotensin-(1–7) [Ang-(1–7)] is a biologically active heptapep-
tide that has been postulated to counterbalance the physiological
actions of angiotensin II (Ang II) within the renin-angiotensin
system (RAS) [1]. Ang-(1–7) was initially regarded as an inactive
component of the RAS for many years [2]. However, in recent
years, several key findings have increased our understanding of the
RAS and the biological significance of Ang-(1–7). This peptide is
present in the circulation and in many tissues, including heart,
vessels and kidney [2].
Numerous experimental and clinical studies have shown that
the inhibition of the ACE-Ang II-AT1 receptor axis reduces renal
dysfunction and fibrosis [3–5]. Therefore, ACE inhibitors (ACEi)
and AT1 receptor blockers (ARBs) have been used as first-line
therapies to reduce the progression of chronic kidney diseases
(CKD) [3,6]. Accumulating evidence suggests that, in addition to
Ang II, Ang-(1–7) also plays a key role in regulating renal function
by acting at glomerular and tubular sites [7–9]. Ang-(1–7)
increased renal blood flow in anesthetized rats, modulated sodium
and water excretion [10,11], reduced urinary protein excretion
[12,13], partially restored renal vascular responsiveness and
produced renal vasodilatation in diabetic SHR rats [14]. The
renal effects of Ang-(1–7) were mimicked by the synthetic oral
agonist of the Mas receptor, the compound AVE 0991 in the
kidney [7] as well in other disease models [15].
On the other hand, there still have been controversial findings
concerning the pathophysiological role of Ang-(1–7) in the context
of normal renal function or during disease states [16,17]. In this
regard, while Pinheiro et al [16] showed that genetic deletion of
Mas receptor in C57BL/6 mice led to glomerular hyperfiltration,
proteinuria and renal fibrosis, Esteban et al [17] reported that
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renal deficiency for Mas diminished renal damage in unilateral
ureteral obstruction and ischemia/reperfusion injury and the
infusion of Ang-(1–7) to wild-type mice elicited inflammatory
response. So far, whether the actions of Ang-(1–7) on renal
function do indeed counter act those of Ang II in the context of
disease states remains to be shown.
In this context, the present study aimed to investigate the
capacity of Mas receptor activation to protect against renal
damage by using the classical model of Adriamycin (ADR)-
induced nephropathy [18,19]. Adriamycin injection mimics
several features of human nephrotic syndrome and is character-
ized by interstitial and glomerular infiltration of leukocytes,
fibrosis, and proteinuria [18,19]. By using this model, we
evaluated whether Mas receptor activation with the oral agonist,
AVE 0991, would have renoprotective effects. We also evaluated
whether the Mas receptor was relevant for the well-known
renoprotection elicited by treatment with AT1 receptor blockers
[3,4].
Materials and Methods
Animals
In the present study, we used Balb/c, FVBN wild-type (Mas+/+)
or FVBN Mas receptor knockout (Mas2/2) mice. All mice were
male and 8–10 weeks old. Mice were maintained under
temperature-controlled conditions with an artificial 12-h light/
dark cycle and were fed standard chow and water ad libitum.
Animals were bred at the animal facility of the Universidade
Federal de Minas Gerais (UFMG) and the study was approved by
the local animals Ethics Committee.
Experimental design
A single dose of ADR (10 mg/kg) (adriablastina rd, Pfizer, SP,
Brazil) [19] was injected in the tail vein of non-anesthetized mice.
Animals developed proteinuria at the seventh day after injection
and were evaluated by three weeks (21 days).
The first set of experiments aimed to investigate the effect of
Mas receptor activation on renal function and histology. These
effects were also compared to those elicited by the AT1 receptor
blocker, Losartan, in the same experimental conditions. Therefore,
we used Balb/c mice randomly divided into 4 experimental
groups: 1) Sham group - animals receiving a single injection of
saline (0.9% NaCl) in the tail vein; 2) Vehicle-treated group -
ADR-injected mice that orally received vehicle (tap water), on
daily basis, from day 7 to day 14 after ADR injection; 3) AVE-
treated group - ADR-injected mice orally treated with 3 mg/Kg of
the Mas receptor agonist, AVE 0991 (Aventis Pharma Deutsch-
land, Frankfurt, Germany), on daily basis, from day 7 to day 14
after ADR injection; 4) Losartan-treated group - ADR-injected
mice that orally received 10 mg/kg of Losartan (Merck Research
Laboratories, Rahway, NJ), on daily basis, from day 7 to day 14
after ADR injection.
The second set of experiments intended to evaluate the putative
role of Mas receptor in contributing to the renoprotective effects of
AT1 receptor blockers upon renal dysfunction and tissue damage.
In this set of experiments, we used FVBN wild-type (Mas+/+) or
FVBN Mas receptor knockout (Mas2/2) mice that received a
single injection of ADR (10 mg/kg) and daily oral doses of AVE
0991 (3 mg/kg) or of Losartan (10 mg/kg), from 7th to 14th day
after ADR injection.
General measurements and renal function parameters
To evaluate the effects of ADR-induced nephropathy, as well as
of the treatment with AVE 0991 or Losartan, on renal physiology,
some parameters were evaluated. First, mice were housed
individually in metabolic cages (Tecniplast, Italy), three days
before ADR or saline injection. Groups of animals (n = 6 to 10)
were sacrificed at 0, 7, 14 and 21 days following ADR or saline
injection. After an adaptation period of three days, urine volume
was measured for the next 24 hours. At the end, 24-hours urine
samples were collected and centrifuged at 3,000 g for 5 min.
Urine was used to determine microalbuminuria and creatinine
concentrations. At the same time-point of urine sampling, blood
samples were collected from the lower abdominal cava vein, under
ketamine and xilazyne anesthesia (150 mg/kg and 10 mg/kg,
respectively), and centrifuged at 2,0006g for 15 min at 4uC. The
resulting plasma samples were used to measure creatinine and
albumin concentrations. Samples of urine and plasma were stored
at 220uC until renal function parameters evaluations.
Creatinine and albumin concentrations were determined by
enzymatic kit (Bioclin/Quibasa, Belo Horizonte, MG, Brazil) and
microalbuminuria was determined by immunoassay (Bioclin/
Quibasa, Belo Horizonte, MG, Brazil).
Systolic blood pressure
In order to evaluate possible changes in blood pressure during
ADR-induced nephropathy, systolic blood pressure (SBP) was
measured by the tail-cuff method using an XBP1000 series rat tail
blood pressure system (Kent Scientific, Torrington, CT), as
described previously [20]. Measurements were performed on the
three days before ADR injections, as an adaptation of the mice at
experimental conditions imposed by equipment. Subsequent
measurements were performed, daily, in the 1st, 4th, 6th, 7th, 14th
and 21st days. Results were reported in mmHg.
Renal histopathology
Paraffin-embedded sections (4-mm thick) were deparaffinized
with xylene and rehydrated through a descending ethanol
gradient. Histological sections were examined following periodic
acid–Schiff staining, and graded according to published standards
[21].
The degree of nephron injury and glomerular fibrosis was
assessed by computer-aided image analysis of PAS-stained kidney
sections. Under a light microscope (Olympus BX51, Japan) field-
images were captured with a digital camera (Megacybernetics)
connected to the microscope. A semiquantitative score (glomerular
and tubular injury index) was used to evaluate the degree of
scarring as described previously [21]. Twenty high-power fields of
renal cortex were randomly selected for assessing tubular
alterations (atrophy, casts, and vacuolization) and interstitial
changes (fibrosis and inflammation) and graded from 0 to 5.
Tubulointerstitial area in the cortex was graded as follows: 0,
normal; 1, area of interstitial inflammation and fibrosis, tubular
atrophy, and vacuolization involving 0–10%; 2, lesion area
between 10–20%; 3, lesion area between 20–30%; 4, lesion area
between 30–40%; and 5, lesions involving 40–100% of the field).
Fifty randomly selected glomeruli were assessed for glomerular
damage (well-developed exudative, mesangial proliferation and
glomeruli hypertrophy), and graded as follows: 0, normal; 1, slight
glomerular damage of the mesangial matrix and/or hyalinosis
with focal adhesion involving 10% of the glomerulus; 2, sclerosis of
10–20%; 3, sclerosis of 20–30%; 4, sclerosis of 30–40%; and 5,
sclerosis of 40–100% of the glomerulus. All scoring was performed
in a blinded manner. The damage was scored semiquantitatively
on a scale of 1 to 5.
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Urinary TGF-b1
Since TGF-b1 has been considered a potential biomarker of
renal tissue fibrosis [22], this cytokine was measured in 24-hour
urine samples after ADR or saline injection. Levels of TGF-b1 in
the urine were assessed by ELISA in accordance with the
procedures supplied by the manufacturer (R&D Systems, Minne-
apolis, MN). Sample of the urine were collected in metabolic cages
and stored at 220uC. Until refrigeration, 10 mL of commercial
protease inhibitor cocktail (Sigma Aldrich, Saint Louis, USA) were
added at urine sample. Results were expressed as relative units of
cytokine per mg of urinary creatinine.
Renal mRNA levels of angiotensin receptors, AT1 and
Mas, and ACE2
Renal mRNA levels for AT1, Mas receptors and ACE2 were
estimated by quantitative real time PCR (polymerase chain
reaction). First, total RNA was extracted from kidneys using
TRIzolH reagent according to the manufacturer’s protocol.
Reverse transcription was performed using 2 mg of total RNA,
200 U of reverse transcriptase, RT buffer 5X (2.5 ml), 10 mM
dNTPs (1.8 ml), RNAsin 10000 U (0.2 ml) and oligo dT 15 50 mM
(1.0 ml). The profile of temperatures for this reaction was: 70uC for
5 min then ice for 2 min, then back to the thermocicler for 42uC
for 60 min, 70uC for 15 min and 4uC as the final step. Resultant
cDNA was used for real time PCR as below. Specific primers were
designed using Primer Express software and synthesized by IDT.
AT1 primer set picks up both AT1a andAT1b receptor subtypes.
Real time PCR was carried out on a StepOne sequence detection
system (Applied Biosystems) using SYBR Green PCR Master Mix
(Applied Biosystems). The relative levels of gene expression were
determined by the comparative threshold cycle method as
described by the manufacturer, in which data for each sample is
normalized to 18S expression.
Statistical analysis
A statistical analysis was performed by GraphPad Prism
software, release 4.0 (GraphPad Software, San Diego, CA). All
data had normal distribution according to the Shaphiro test.
Results are expressed as the mean 6 SEM. Differences between
groups were evaluated by ANOVA, followed by a Student–
Newman–Keuls test. The level of significance was set at p,0.05.
Results
Time-course of the renal changes following ADR-induced
nephropathy
All experimental animals injected with ADR developed
nephropathy characterized by proteinuria, hypoalbuminemia,
and progressive renal injury. As shown in Table 1, injection of
ADR resulted in reduction in body weight that was clear at day 7
day and persisted till day 21. Systolic blood pressure raised
progressively from day 7 to day 14 and was still elevated at day 21
as compared to the control group (day 0). Microalbuminuria was
detectable at day 7 and was 45-fold greater than baseline at day 21
after disease induction. Loss of albumin in urine was associated
with marked fall of serum albumin at all time points evaluated
(Table 1). There was no change in serum creatinine throughout
the observation period, but urinary creatinine was below control
values at days 14 and 21 after ADR injection (Table 1).
Histopathologic and scoring evaluation in ADR-induced
nephropathy
Adriamycin induced both glomerular and tubule-interstitial
changes. The severity of changes increased progressively in the
renal cortex from day 7 to day 14 and stabilized on 21 (Figure 1A–
H). ADR induced nephropathy probably by direct toxic damage
to the glomerulus with subsequent tubule-interstitial injury in
contrast to the normal glomerular and tubular aspects noticed in
sham-operated mice (Figure 1 A, B). At day 7, there was discrete
glomerular changes, including segmental fibrin deposition
(Figure 1C, arrow), discrete tubular cell damage (figure 1D,
arrowheads), expansion of interstitial space and discrete enlarge-
ment of tubules. At day 21, focal segmental sclerosis (Figure 1G,
arrow) was detected in a small percentage of glomerulus and there
was tubular regeneration (Figure 1H, arrowheads).
At day 14 following ADR administration, significant glomerular
and tubular injury associated with interstitial inflammation was
observed, as shown in Figure 1E and F. There was glomerular
enlargement due to significant increase in mesangial matrix area
and increased percentage of sclerotic glomeruli (range 40 to
100%), accompanyied by variable degrees of mesangial expansion,
increased mesangial cellularity, segmentation, capillary oblitera-
tion and formation of cell bridges between the tuft and Bowman’s
capsule (Figure 1E, arrow). In addition, global sclerosis was
observed in many glomeruli (Figure 1E, asterisks). Tubules
displayed severe changes, including decrease in height of tubular
epithelial cells (tubular atrophy) and vacuolization. Intra-tubular
eosinophilic large cast formation (Figure 1F and inset, thin arrows)
and focal increase in reabsorption droplets in tubular cells were
also observed (Figure 1F, arrowheads). The interstitial volume
increased mildly and focally and there was a discrete infiltration of
mononuclear cells. Less frequently, glomeruli with minimal lesions
embedded in normal tubules could be found adjacent to severely
damaged areas, indicating the focal nature of the disease process.
The degree of glomerular and tubular injury was graded as mild
injury at day 7, changes were maximum at day 14 and tended to
attenuate at day 21 following ADR administration. By 21 days,
some glomeruli were reduced in size with several vacuoles, collapse
and segmentation of tuft, but mostly the damage scores were
reduced. As disease was maximal at day 14, this time point was
chosen for subsequent experiments. Scores for glomerular and
tubule-interstitial damage averaged 4.2 and 4.6, respectively, at 14
days after ADR administration. These values were significantly
higher than those in Sham-operated animals (Glomerular damage,
Sham, 0.2460.04 vs ADR, 4.260.37; Tubule-interstitial damage,
Sham, 0.060.0 vs ADR, 4.660.25, respectively).
Renal effects of AVE0991 or Losartan administration in
ADR-induced nephropathy
Mice were treated with the Mas receptor agonist, AVE 0991
(3 mg/kg), from day 7 to day 14, as an attempt to mimic the real
clinical situation, ie. patients arriving with some degree of injury,
but not full blown renal damage. As shown in Figure 2, treatment
with AVE 0991 had significant beneficial effects on ADR-induced
renal dysfunction and injury. Parallel experiments were carried out
with the AT1 receptor antagonist, Losartan, which had similar
protective effects to those of AVE 0991. Indeed, renal excretion of
albumin was significantly reduced by treatment with AVE 0991
(51% decreased, p,0.01, n= 6) or Losartan (34%, p,0.05, n= 6)
(Figure 2A). Although injection of ADR induced a decrease in
serum levels of albumin (see Table 1), there was no reversion of
this parameter by the treatments with the compounds, AVE or
Losartan (Figure 2B). Urinary levels of TGF-b were increased at
Mas Receptor in Adriamycin-Induced Nephropathy
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day 14 in mice given adriamycin. Treatment with AVE 0991 also
reduced urinary levels of TGF-b1 (Figure 2C).
Figure 3 shows some of the major changes in the renal
architecture of mice given adriamycin and that were subsequently
treated with vehicle (Figure 3A–B), AVE 0991 (Figure 3C–D) or
Losartan (Figure 3E–F). Glomerular and tubular injuries observed
in vehicle-treated mice were attenuated by treatment with AVE
0991 or Losartan, as it can be seen by the semi-quantitative
analysis (Figure 3G–H). In both treatments, there was reduction in
the intensity of mesangial expansion, mesangial cellularity,
adhesion formation (open arrows) and number of glomeruli which
were affected, as shown by the arrows. Similar protection occurred
in the renal tubules with reduction of focal areas of proteinaceous
casts (thin arrows).
Role of ACE2/Ang-(1–7)/Mas receptor activation in ADR-
induced nephropathy and potential interactions with AT1
antagonists
Expression levels of angiotensin receptors, AT1 and Mas, and
ACE2 were evaluated by real time PCR. As shown in Figure 4A,
there was marked reduction of expression of both receptors in the
kidney after the administration of ADR (Figure 4A). Mas receptor
mRNA expression was mostly decreased at day 14, whereas levels
of AT1 mRNA were lowest at day 21. Treatment with Losartan
greatly increased by about 280-fold the expression of Mas receptor
mRNA in the kidneys of animals given adriamycin (10 mg/kg)
(Figure 4B). Losartan treatment did not alter the levels of AT1
receptor mRNA (Figure 4B). Renal expression of ACE2 mRNA
was significantly increased following Losartan treatment
(Figure 4C).
Mice with genetic deletion of Mas receptor in FVB/N
background (Mas2/2) were given ADR in order to evaluate the
role of endogenous Mas receptor in this model of nephropathy. As
displayed in Figure 5 (A–B and E–F), histological changes of ADR-
induced nephropathy were similar in Mas2/2 and wild type mice
(Mas+/+). To evaluate the contribution of Mas receptor for the
renoprotective actions caused by the treatment with the AT1
antagonist Losartan, a dose of 10 mg/Kg of this medication was
also given to Mas2/2 and Mas+/+ mice with ADR-induced
nephropathy. The treatment with Losartan was able to reduce
renal histological injury indexes only inMas+/+, but not inMas2/2
mice (Figure 5C–D and 5G–H). Scores for glomerular and tubule-
interstitial damage are shown in Figures 5I and 5J, respectively.
Discussion
Major findings of the present study can be summarized as
follows: (i) treatment with AVE 0991, an orally-active Mas
Table 1. Time course of adriamycin-induced renal dysfunction.
Days Weight (g)
Systolic Blood Pressure
(mmHg) Microalbuminuria U P/C
Serum Albumin
(mg/ml)
Urinary Creatinine
(mg/ml)
Plasma
Creatinine
(mg/ml)
0 25.560.7 82.463.7 0.00860.004 2.460.08 820.4663.3 2.460.5
7 20.260.8*# 93.362.1* 0.1860.03* # 1.560.2* # 704.3675.5 2.860.4
14 22.960.9* 99.863.6*# 0.3660.05* # 1.860.06*# 464.1680.3*# 2.660.4
21 22.261.7* 91.163.5* 0.3760.09* 1.960.05 * 534.8636.3* 2.860.3
Adriamycin (10 mg/kg) was injected in the tail vein of Balb/c mice. The following parameters were evaluated at days 7, 14 and 21 after ADR injection: mean body weight
(g), systolic blood pressure (mmHg), albumin/creatinine ratio, serum albumin (g/dL), urinary and serum creatinine (mg/dl). Results are mean 6 SEM of 6–10 mice per
group. (*) for P,0.01 when compared to day 0.
doi:10.1371/journal.pone.0066082.t001
Figure 1. Adriamycin-induced morphological changes in
glomerular and tubular regions of the kidney. Representative
photographs of PAS-stained glomerular and tubular regions noticed in
control mice (Sham, A, B), and 7 (C, D), 14 (E, F) and 21 (G, H) days after
injection of adriamycin (10 mg/kg). Glomerular damage (large arrows),
tubule-interstitial changes, atrophy of tubular epithelial cells (arrow-
heads) and tubular enlargement (thin arrows, insert) increased in the
renal cortex from day 7 (D) to day 14 (F, insert, arrow). Global sclerosis
was observed in many glomeruli (E, asterisks). Resorption droplets were
present in tubular cells at day 14 (panel F, thin arrows). Histological
changes stabilized on day 21 (G, H). Original magnification 406
objective.
doi:10.1371/journal.pone.0066082.g001
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receptor agonist, significantly improved renal function parameters,
reduced urinary protein loss and attenuated histological changes in
a murine model of ADR-induced nephropathy. (ii) Renoprotective
actions of AVE 0991 were very similar to those produced by the
administration of Losartan, an AT1 receptor antagonist. (iii)
Renoprotection induced by AVE 0991 was associated with
reduction in urinary levels of the fibrogenic cytokine, TGFb1.
(iv) In ADR-induced nephropathy, mRNA expression for both
angiotensin receptors, AT1 and Mas, were decreased. On the
other hand, the treatment with Losartan significantly increased the
mRNA expression for Mas receptor and for ACE2 in renal tissue.
(v) Finally, renoprotective effects of Losartan were blunted in mice
with genetic deletion of Mas receptor, demonstrating that Mas
receptor activation is essential for the renoprotective effects of AT1
receptor antagonists.
ADR-induced nephropathy in mice mimics several aspects of
the renal dysfunction observed in human nephrotic syndrome
[23]. It is considered to be an experimental model of focal
segmental glomerulosclerosis, which is characterized by interstitial
infiltration, glomerular fibrosis, and proteinuria [18,19,24].
Figure 2. Effects of the treatment with the Mas receptor agonist, AVE 0991, and the AT1 receptor blocker, Losartan, on adriamycin-
induced renal injury. Adriamycin (ADR, 10 mg/kg) was injected in the tail vein of Balb/c mice. Animals were treated daily with vehicle (VE, filtered
water), AVE0991 (AVE, 3 mg/kg) or Losartan (LOS, 10 mg/kg) by gavage from days 7 to day 14 day after ADR injection. The sham group received a
single injection of NaCl 0.9% in the tail vein and was treated with filtered water. Microalbuminuria (A) and serum albumin levels (B) were evaluated on
day 14 in n = 6–10 mice per group. The panel also shows urinary levels of TGF-b (C) in n = 4–5 mice per group. (*) for P,0.05 when compared to VE
group and (#) for P,0.05 when compared to sham group.
doi:10.1371/journal.pone.0066082.g002
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Figure 3. Histological changes and index of tubulointertitial and glomerular injury of ADR-induced nephrosis at day 14. Adriamycin
(10 mg/kg) was injected in tail vein of Balb/c mice, on day 0 in vehicle-treated, VE (filter water), AVE0991-treated, AVE, (AVE 0991, 3 mg/kg) and
Losartan-treated, LOS groups (losartan, 10 mg/kg). Representative photographs of PAS stained of glomerular and tubular regions were obtained at
14th day. All mice were treated by gavage, daily, 7th to 14th day after ADR-induction. Glomerular (large arrow) and tubular injuries (thin arrows)
Mas Receptor in Adriamycin-Induced Nephropathy
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66082
Accordingly, we have found increased urinary protein excretion,
reduced serum albumin, mild elevation in systolic blood pressure
and significant histological changes in glomerular and tubular
compartments, as it has been reported in other studies [19,25–27].
Our study represents the first evidence of renoprotection
obtained with Mas receptor activation by oral administration of
its agonist, AVE 0991, in ADR-induced nephropathy. Studies
using mice with genetic deletion of the Mas receptor showed
observed in vehicle-treated mice (A–B) were attenuated by treatment with AVE 0991 (C–D) or Losartan (E–F). Original magnification 46objective (A,
C) and 406 (B, D). The indexes of tubulointerstitial (G) and glomerular (H) injuries were graded in a blind manner, as described in methods section.
Symbols represent results in single animals and the trace is median value for 5–8 animals. (*) for P,0.05 when compared to 14th day after ADR-
induction group and (#) for P,0.05 when compared to sham group.
doi:10.1371/journal.pone.0066082.g003
Figure 4. mRNA expression of Mas, AT1 and ACE2 in the kidneys after injection of adriamycin. In A, Mas and AT1 mRNA levels were
evaluated in the kidney before (Sham) and 7, 14 and 21 days after injection of adriamycin (ADR, 10 mg/kg). In B, Mas and AT1 mRNA levels at day 14
in kidneys of mice injected with adriamycin that were treated with vehicle (VE) or losartan (LOS, 10 mg/kg). In C, ACE2 mRNA levels at day 14 in
kidneys of mice injected with adriamycin that were treated with vehicle (VE) or losartan (LOS, 10 mg/kg). The dotted line across the graphs represents
levels in control animals. Renal mRNA levels of receptors and ACE2 were estimated by real time PCR. Results are mean6 SEM of n = 5 mice per group.
(*) for P,0.05 when compared to sham group.
doi:10.1371/journal.pone.0066082.g004
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Figure 5. Treatment with losartan protects from adriamycin-induced renal damage in wild type (Mas+/+) but not Mas deficient
(Mas2/2) mice. Adriamycin (10 mg/kg) was injected in the tail vein of Mas+/+ (A–D) and Mas2/2 (E–H) FVBN mice. Animals were treated with water
Mas Receptor in Adriamycin-Induced Nephropathy
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controversial results in relation to renal function and renal
histopathology in different models [16,17]. While Pinheiro et al
(2009) [16] showed that the genetic deletion of Mas receptor in
C57Bl/6 background mice led to glomerular hyperfiltration,
proteinuria and renal fibrosis, Esteban et al (2009) [17] reported
that renal deficiency of Mas diminished renal damage in unilateral
ureteral obstruction and ischemia/reperfusion injury, and that the
infusion of Ang-(1–7) to wild-type mice elicited an inflammatory
response. Furthermore, animal models of renal diseases have also
shown discrepant findings [26,27]. Zhang et al [27] showed that a
5-day infusion of Ang-(1–7) reduced proteinuria and improved
glomerulosclerosis in a rat model of thy-1 induced glomerulone-
phritis, whereas van der Wouden et al reported that infusion of
Ang-(1–7) was not able to reduce proteinuria in ADR-induced
nephropathy [26]. Velkoska et al (2011) showed that a 10 day
infusion of Ang-(1–7) in rats with subtotal nephrectomy was
associated with deleterious effects on blood pressure and the heart,
with increase in cardiac ACE, and decrease in cardiac ACE2
activity [28]. Dilauro et al (2010) suggested a renoprotective action
for ACE2 activation, while no effect was obtained following Ang-
(1–7) infusion in mice subjected to subtotal nephrectomy [25].
Consequently, the effects of Ang-(1–7) in the kidney appear to be
importantly influenced by experimental conditions and the
previous level of RAS activation. Indeed, differences between
species, local and systemic concentrations of Ang-(1–7), nephron
segment, level of RAS activation and sodium and water status can
be responsible for these divergent effects on renal function
[25,26,28]. In this study, we have clearly shown renoprotective
effects of AVE0991 in a murine model of ADR-induced
nephropathy. Oral administration of this Mas receptor agonist
significantly improved renal function parameters, reduced urinary
protein loss and protected against renal tissue damage.
Immunohistochemical data have shown a similar distribution
for Ang-(1–7), ACE2 and Mas within the kidney [29], placing the
key components together for activation and activity. Mas receptor
was detected at different nephron segments such as the juxtaglo-
merular apparatus, proximal tubules, and collecting ducts of mice
[16] and at both cortical and medullar regions of rat kidneys [30].
Consistent with the latter finding, it has been shown that the
biological effects of Ang-(1–7) in the kidney are primarily mediated
by Mas [7,8,16]. Mas-deficient mice have fluid retention,
glomerular hyperfiltration, microalbuminuria, increased collagen
deposition and mRNA overexpression of AT1 receptor and TGF-
b in renal tissues [16]. These results indicate that the lack of Mas
may lead to RAS imbalance with unopposed actions of the ACE/
Ang II/AT1 axis in the kidney.
Although several studies demonstrate divergent roles to
endogenous Mas receptor activation on progression of the renal
disease (Pinheiro and Esteban, for example) [16,17], the present
study demonstrated another important finding: the absence of Mas
receptor did not affect ADR-induced injury, suggesting that the
role of endogenous activation of Mas receptor is not as relevant as
the beneficial effects of exogenous stimulation by AVE 0991
administration. Recently, we demonstrated similar effect in a
model of renal ischemia and reperfusion, in which Mas KO mice
presented similar levels of creatinine and of renal neutrophil influx
when compared to wild type mice [31]. We have also shown a
minor role for Mas deficiency in worsening the injury observed in
an antigen-induced-arthritis mice model (AIA), while pharmaco-
logical activation of Mas receptor had meaningful biological effects
and efficiently controlled articular inflammation in the same
experimental model [32]. Despite the absence of an endogenous
role for Mas receptor, it is clear that the exogenous activation of
this receptor provided important renoprotective effects in the
context of ADR-induced nephropathy.
The pathways by which AVE 0991 reduced proteinuria and
attenuated renal tissue injury were not fully elucidated. The
detection of proteinuria in ADR-induced animals suggests direct
podocyte injury. Previous studies also support the direct role of
ARBs in renal podocytes [33–35]. Matsusaka et al (2010) showed
that ARBs attenuated podocyte injury, proteinuria, and glomer-
ulosclerosis in the NEP25 model [33]. The podocyte protection
was independent of the local inhibition of AT1 receptors. Naito et
al (2010) showed, in a model of 5/6 nephrectomy, that the
podocyte protection following ARBs treatment was due not only to
the blockade of AT1 receptor, but also to Ang II effects mediated
by AT2 receptor [34]. More recently, Shimizu et al (2012) also
showed that ARB exerts podocyte protection in a mice model of
HIV-1 nephropathy. In the present study, we did not evaluate the
direct effect of Losartan or AVE 0991 on podocytes [35].
However, the treatment with both Losartan and AVE0991
reduced urinary protein loss and glomerulosclerosis.
Another important pathway elicited by Losartan and AVE 0991
treatment was the reduction of renal levels of TGF-b in the present
experimental model. TGF-b expression in the kidney is thought to
be a final common pathway leading to the development of
structural damage and fibrosis in a range of glomerular diseases
[36,37]. This cytokine can be synthesized by numerous cells
including macrophages, T and B lymphocytes fibroblasts, and
resident renal cells. By binding to AT1 receptor, Ang II may
promote progression of renal fibrosis via the production of TGF-
b1 [38]. In this regard, Crowley et al (2009) showed that the
administration of the AT1 receptor antagonist, Losartan, signifi-
cantly reduced the mRNA expression for TGF-b in renal tissue,
whereas animals with genetic deletion of this receptor exhibited an
increased expression of the cytokine [39]. Accordingly, our study
also showed that Losartan reduced renal tissue levels of TFG-b in
ADR-induced nephropathy.
Recent studies indicated that the activation of ACE2-Ang-(1–7)-
Mas receptor axis might attenuate fibrogenic processes by
decreasing TGF-b levels or expression in many tissues [40–45].
For instance, in variours models of myocardial hypertrophy, the
administration of Ang-(1–7) or AVE 0991 reduced local levels of
TGF-b and produced cardiac remodeling [41]. Once again,
studies have shown divergent results concerning renal tissue.
Consistent with our findings, it was previously shown that Ang-(1–
7) decreased TGF-b levels in rat proximal tubular cells [44] and
reduced renal fibrosis in experimental diabetic nephropathy [45].
Su et al (2006) showed that Ang-(1–7) inhibited Ang II-stimulated
phosphorylation of ERK1/2, p38 MAPKs and c-Jun N-terminal
kinase in culture rat proximal tubular cells, an effect reversed by
pre-treatment with A-779. Ang-(1–7) also prevented Ang II-
induced production of TGF-b1 in proximal tubular cells. Thus,
the generation of Ang-(1–7) by proximal tubular ACE2 could
counteract the proliferative effects of locally produced Ang II [42].
In addition, the genetic deletion of Mas receptor led to high
(VE, A–B and E–F) or Losartan (LOS, 10 mg/kg, C–D and G–H) and morpohological changes evaluated at day 14 after adriamycin injection. Glomerular
(large arrow) and tubular injuries (thin arrows) are showed. Indices of tubulointerstitial (I) and glomerular (J) injuries were graded in a blind manner, as
described in the Methods section. PAS-stained sections and magnification 106 (A, C, E, G) and 406 (B, D, F, H). Symbols represent results in single
animals and the trace is median value. (*) for P,0.05 when compared to VE-treated group and (#) for P,0.05 when compared to sham group.
doi:10.1371/journal.pone.0066082.g005
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mRNA expression of TGF-b in renal tissue [16]. In contrast, other
authors reported that Ang-(1–7) increased TGF-b in human renal
mesangial cells (56) and accelerated the progression of experi-
mental diabetic nephropathy [44,45]. Although these findings are
conflicting, cell-specific signaling pathways associated with Ang-
(1–7) in the kidney could play a role in the variable response. In
this study, we have detected a decrease in renal TGF-b levels
elicited by the Mas receptor agonist administration. Our data
support an anti-fibrogenic role for ACE2-Ang-(1–7)-Mas receptor
axis at renal tissue, as previously demonstrated for heart [46] and
liver tissues [47].
AT1 receptor antagonism is considered a first-line strategy to
control the progression of chronic kidney diseases [3,6]. For this
reason, the renal effects of AVE 0991 administration were
compared with those related to the treatment with Losartan, an
AT1 receptor antagonist. It was noteworthy that AVE0991 and
Losartan reduced histological injury indexes, urinary protein and
TGF-b levels in the same way. The renoprotective actions of
ARBs clearly involve multiple pathways including anti-prolifera-
tive and anti-fibrogenic effects [3,6,48,49]. In particular, an altered
balance between Ang II and Ang-(1–7) might be related to the
mechanism of action of AT1 receptor blockade, since this
treatment increased the circulating levels of Ang-(1–7) [50,51].
In addition, Kostenis et al (2008) suggested that the Mas receptor
is a physiologic antagonist of the AT1 receptor [52].
Therefore, we evaluated whether the presence of Mas receptor
was relevant for the described protective effects of the treatment
with AT1 receptor blockers by using mice with genetic deletion of
Mas receptor (Mas2/2). Mas2/2 animals exhibited the same
degree of histological injury when compared to wild type mice
(Mas+/+). On the other hand, the treatment with Losartan was
able to attenuate renal injury only in Mas+/+ mice, but not in
Mas2/2 animals. It would have been interesting to examine
whether, in Mas knockout mice, AVE 0991 compound could
improve or not ADR-induced renal damage. Previous studies of
our group showed that AVE 0991 was not able to affect renal
function parameters [16] or leukocyte infiltration in experimental
arthritis [15] in Mas KO animals. In addition, the binding of AVE
0991 to renal tissue was absent in Mas KO animals [16].
Therefore, based on the selectivity of the compound and previous
results of our group, we do believe that the presence of Mas
receptor is critical for the renoprotective effects of AVE 0991.
It should also be considered that this model of nephropathy
produced significant reduction in the mRNA expression for both
angiotensin receptors, Mas and AT1, but the treatment with
Losartan increased only the expression of Mas receptor, without
changing mRNA levels for AT1 receptor. Moreover, Losartan also
increased renal expression of ACE2, the main responsible for Ang-
(1–7) synthesis at renal tissue [53]. Corroborating the present data,
previous studies reported similar effects of ARBs on the
modulation of ACE2Ang-(1–7)/Mas receptor axis at different
sites [54–58]. In this regard, Ferrario et al (2005) showed that
Losartan increases plasma and urinary levels of Ang-(1–7) and
renal ACE2 activity, without changing the expression of Mas
receptor, AT1 or ACE in Lewis rats. Igase et al (2011) in a model
of hypertensive nephropathy showed that olmesartan treatment
increased plasma levels of Ang-(1–7) leading to cardiprotective and
renoprotective effects [55]. In a model of ADR-induced heart
failure in Male Sprague-Dawley rats, Zong et al (2011) detected a
decrease of plasma Ang-(1–7) levels and reduced myocardial
expression of Mas receptor, while the treatment with telmisartan
or losartan increased Ang-(1–7) levels and suppressed myocardial
AT1 receptor expression without changing the expression of Mas
[58]. Recent studies of Sukumaran et al (2011 and 2012) showed
that the protein and mRNA levels of Mas receptor, ACE2 and
Ang-(1–7) were upregulated in olmesartan treated group in
experimental autoimmune myocarditis and these changes in
RAS components decreased the expression of inflammatory
markers [56,57]. Taken together, these findings indicated that
ACE2/Ang-(1–7)/Mas receptor axis activation participate in the
renoprotection triggered by ARB
In conclusion, this study shows that the Mas receptor agonist,
AVE0991, has renoprotective actions in ADR-induced nephrop-
athy. The effects of AVE0991 were comparable to those of the
AT1 receptor antagonist, Losartan. Beneficial effects of AVE0991
and of Losartan were related to the reduction of urinary levels of
the fibrogenic cytokine, TGF-b. Furthermore, the presence of Mas
receptor seemed to be critical for the renoprotective actions of AT1
antagonists. Further research on the contribution of the ACE2/
Ang-(1–7)/Mas axis to renal pathophysiology should lead to the
development of new pharmacological approaches for human
nephropathies.
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